Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Medicare Issues Final Coverage Determination For Healthcare Company

Medicare Issues Final Coverage Determination for KidneyIntelX.dkd: A Detailed Overview.
Renalytix plc, a company listed on NASDAQ under the ticker symbol RNLX and also on the London Stock Exchange as RENX, has announced a pivotal development in the coverage of its KidneyIntelX.dkd testing. On June 13, 2024, Medicare issued a final Local Coverage Determination (LCD) for KidneyIntelX.dkd, a diagnostic tool designed to aid in the management of kidney disease among patients with Type 2 diabetes. This decision is set to take effect for dates of service on or after August 1, 2024. The significance of this determination is profound, given the prevalence of kidney disease among diabetic patients in the United States. $Renalytix(RNLX.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
4758 Views
Comment
Sign in to post a comment
    176Followers
    0Following
    399Visitors
    Follow